Maze Therapeutics (MAZE) director awarded 18,000 stock options at $23.58 exercise price

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Maze Therapeutics director Charles J. Homcy received a grant of stock options covering 18,000 shares of common stock. The options have an exercise price of $23.58 per share and expire on June 7, 2036. They will vest and become fully exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027, subject to his continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider HOMCY CHARLES J

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	18,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 18,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 18,000 options Exercise price: $23.58 per share Expiration date: June 7, 2036 +2 more

5 metrics

Options granted 18,000 options Stock Option (Right to Buy) grant on 2026-06-08

Exercise price $23.58 per share Exercise price for 18,000 underlying common shares

Expiration date June 7, 2036 Option expiration for this grant

Total options after grant 18,000 options Total derivative securities owned following transaction

Vesting date Earlier of 2027 meeting or June 8, 2027 Vesting contingent on continued service

Key Terms

Stock Option (Right to Buy), exercise price, vesting, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "23.5800" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option shall vest and be fully exercisable on the earlier of..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2036-06-07T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/10/2026 - 04:26 PM Accepted by SEC EDGAR 06/10/2026 - 04:25 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HOMCY CHARLES J

(Last)

(First)

(Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$23.58	06/08/2026		A		18,000		⁽¹⁾	06/07/2036	Common Stock	18,000	$0	18,000	D

Explanation of Responses:

1. The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Maze Therapeutics (MAZE) disclose in this Form 4 for Charles J. Homcy?

Maze Therapeutics reported a stock option grant to director Charles J. Homcy for 18,000 shares of common stock at a $23.58 exercise price. The options represent compensation and are not an open-market purchase or sale of existing shares.

How many Maze Therapeutics (MAZE) shares are covered by the new stock options?

The grant covers options on 18,000 shares of Maze Therapeutics common stock. These options give the director the right to buy shares at a fixed exercise price once they vest, aligning part of his compensation with the company’s future stock performance.

What is the exercise price of the new Maze Therapeutics (MAZE) stock options?

The options have an exercise price of $23.58 per share. This means Charles J. Homcy can purchase Maze Therapeutics common stock at $23.58 per share once the options vest and are exercised, regardless of the market price at that time.

When do Charles J. Homcy’s Maze Therapeutics (MAZE) options vest?

The options vest and become fully exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027. Vesting is conditioned on Homcy’s continued service to Maze Therapeutics through that vesting date, according to the filing footnote.

When do the newly granted Maze Therapeutics (MAZE) stock options expire?

The options expire on June 7, 2036. After this expiration date, any unexercised options become worthless and can no longer be used to purchase Maze Therapeutics common stock at the stated $23.58 exercise price.

Is this Maze Therapeutics (MAZE) Form 4 a market buy or sell by Charles J. Homcy?

No. The Form 4 reports a grant of stock options as compensation, coded as an acquisition (A), not an open-market trade. Homcy did not buy or sell existing shares in the market; he received options that may be exercised in the future.